Phase III trial data support obicetrapib's lipid controlling effects in high-risk individuals without sufficient response to other lipid-lowering therapies. Obicetrapib is a highly selective CETP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback